Effects of inhaled formoterol compared with salbutamol in ventilated preterm infants

Pulm Pharmacol Ther. 2004;17(5):293-300. doi: 10.1016/j.pupt.2004.06.003.

Abstract

Background: Short-acting beta(2)-agonists have shown beneficial effects in preterm infants, but data on long acting beta(2)-agonists are still lacking.

Objectives: To compare the effects of inhaled formoterol with salbutamol in preterm infants.

Methods: Randomized, double-blind, crossover design of salbutamol (100 microg every 6 h) or formoterol (12 microg every 12 h) delivered by metered dose inhaler on two consecutive days to very low birth weight infants on assisted mechanical ventilation (n=12; gestational age 25.7+/-2 weeks; birth weight 720+/-254 g; postnatal age 25+/-9 days; mean+/-SD). Treatment with the second drug was administered until day 7 in eight infants. Outcome variables were minute volume MV, respiratory mechanics, heart rate HR, blood pressure, serum potassium and blood glucose levels.

Results: Mean MV increased by maximal 26% (salbutamol) and by 22% (formoterol) differing from baseline values until 6 and 8 h through increased mean tidal volume (Vt) in both groups (max. 14%). Mean static compliance (Crs) increased by 26% (salbutamol) and by 32% (formoterol) until 60 min post-administration. There was no tachyphylaxis.

Conclusion: Inhaled salbutamol and formoterol equally increase MV, Vt, Crs and HR in mechanically ventilated infants with a longer lasting systemic effect of formoterol.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adrenergic beta-Agonists / therapeutic use*
  • Albuterol / therapeutic use*
  • Cross-Over Studies
  • Double-Blind Method
  • Ethanolamines / therapeutic use*
  • Formoterol Fumarate
  • Heart Rate / drug effects
  • Heart Rate / physiology
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Very Low Birth Weight
  • Metered Dose Inhalers
  • Respiration
  • Respiration, Artificial*
  • Respiratory Distress Syndrome, Newborn / therapy*
  • Tidal Volume / drug effects
  • Tidal Volume / physiology
  • Treatment Outcome

Substances

  • Adrenergic beta-Agonists
  • Ethanolamines
  • Albuterol
  • Formoterol Fumarate